{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T13:40:08Z","timestamp":1747057208354,"version":"3.40.5"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T00:00:00Z","timestamp":1741392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T00:00:00Z","timestamp":1741392000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2022\/03316-8","2022\/11038-8","2020\/12842-0","2021\/11606-3"],"award-info":[{"award-number":["2022\/03316-8","2022\/11038-8","2020\/12842-0","2021\/11606-3"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["305758\/2021-7"],"award-info":[{"award-number":["305758\/2021-7"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","award":["Finance Code 001"],"award-info":[{"award-number":["Finance Code 001"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s43440-025-00711-y","type":"journal-article","created":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T13:40:29Z","timestamp":1741441229000},"page":"817-828","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Eribulin exerts multitarget antineoplastic activity in glioma cells"],"prefix":"10.1007","volume":"77","author":[{"given":"Guilherme Augusto Sousa","family":"Alc\u00e2ntara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariane Cristina","family":"do Nascimento","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Livia Bassani Lins","family":"de Miranda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruna Oliveira","family":"de Almeida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keli","family":"Lima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo Magalh\u00e3es","family":"Rego","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leticia Veras","family":"Costa-Lotufo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2937-8109","authenticated-orcid":false,"given":"Jo\u00e3o Agostinho","family":"Machado-Neto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,8]]},"reference":[{"key":"711_CR1","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41572-024-00516-y","volume":"10","author":"M Weller","year":"2024","unstructured":"Weller M, Wen PY, Chang SM, Dirven L, Lim M, Monje M, et al. Glioma. Nat Rev Dis Primers. 2024;10:33.","journal-title":"Nat Rev Dis Primers"},{"key":"711_CR2","doi-asserted-by":"publisher","first-page":"i1","DOI":"10.1093\/neuonc\/noad149","volume":"25","author":"QT Ostrom","year":"2023","unstructured":"Ostrom QT, Price M, Neff C, Cioffi G, Waite KA, Kruchko C, et al. CBTRUS e United States in 2016\u20132020. Neuro Oncol. 2023;25:i1-iv99.","journal-title":"Neuro Oncol."},{"key":"711_CR3","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s13046-022-02349-7","volume":"41","author":"L Rong","year":"2022","unstructured":"Rong L, Li N, Zhang Z. Emerging therapies for glioblastoma: current state and future directions. J Exp Clin Cancer Res. 2022;41:142.","journal-title":"J Exp Clin Cancer Res"},{"key":"711_CR4","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1358\/dot.2010.46.9.1519020","volume":"46","author":"S Mani","year":"2010","unstructured":"Mani S, Swami U. Eribulin mesilate, a halichondrin B analogue, in the treatment of breast cancer. Drugs Today (Barc). 2010;46:641\u201353.","journal-title":"Drugs Today (Barc)"},{"key":"711_CR5","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1158\/1535-7163.MCT-04-0345","volume":"4","author":"MA Jordan","year":"2005","unstructured":"Jordan MA, Kamath K, Manna T, Okouneva T, Miller HP, Davis C, et al. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther. 2005;4:1086\u201395.","journal-title":"Mol Cancer Ther"},{"key":"711_CR6","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1124\/mol.106.026641","volume":"70","author":"DA Dabydeen","year":"2006","unstructured":"Dabydeen DA, Burnett JC, Bai R, Verdier-Pinard P, Hickford SJ, Pettit GR, et al. Comparison of the activities of the truncated halichondrin B analog NSC 707389 (E7389) with those of the parent compound and a proposed binding site on tubulin. Mol Pharmacol. 2006;70:1866\u201375.","journal-title":"Mol Pharmacol"},{"key":"711_CR7","doi-asserted-by":"publisher","first-page":"e482s","DOI":"10.6061\/clinics\/2018\/e482s","volume":"73","author":"PC Jimenez","year":"2018","unstructured":"Jimenez PC, Wilke DV, Costa-Lotufo LV. Marine drugs for cancer: surfacing biotechnological innovations from the oceans. Clinics (Sao Paulo). 2018;73:e482s.","journal-title":"Clinics (Sao Paulo)"},{"key":"711_CR8","doi-asserted-by":"publisher","first-page":"157","DOI":"10.52586\/S559","volume":"13","author":"P Seshadri","year":"2021","unstructured":"Seshadri P, Deb B, Kumar P. Multifarious targets beyond microtubules-role of eribulin in cancer therapy. Front Biosci (Schol Ed). 2021;13:157\u201372.","journal-title":"Front Biosci (Schol Ed)"},{"key":"711_CR9","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.critrevonc.2011.03.002","volume":"81","author":"U Swami","year":"2012","unstructured":"Swami U, Chaudhary I, Ghalib MH, Goel S. Eribulin\u2014a review of preclinical and clinical studies. Crit Rev Oncol Hematol. 2012;81:163\u201384.","journal-title":"Crit Rev Oncol Hematol"},{"key":"711_CR10","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1111\/cas.14067","volume":"110","author":"M Takahashi","year":"2019","unstructured":"Takahashi M, Miki S, Fujimoto K, Fukuoka K, Matsushita Y, Maida Y, et al. Eribulin penetrates brain tumor tissue and prolongs survival of mice harboring intracerebral glioblastoma xenografts. Cancer Sci. 2019;110:2247\u201357.","journal-title":"Cancer Sci"},{"key":"711_CR11","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1111\/cas.13637","volume":"109","author":"S Miki","year":"2018","unstructured":"Miki S, Imamichi S, Fujimori H, Tomiyama A, Fujimoto K, Satomi K, et al. Concomitant administration of radiation with eribulin improves the survival of mice harboring intracerebral glioblastoma. Cancer Sci. 2018;109:2275\u201385.","journal-title":"Cancer Sci"},{"key":"711_CR12","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1200\/JCO.2022.40.16_suppl.2036","volume":"40","author":"M Takahashi","year":"2022","unstructured":"Takahashi M, Kawashima S, Otake Y, Satomi-Tsushita N, Kuchiba A, Sadachi R, et al. A phase II, multicenter, single-arm trial of eribulin in patients with bevacizumab-resistant recurrent glioblastoma. J Clin Oncol. 2022;40:2036.","journal-title":"J Clin Oncol"},{"key":"711_CR13","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402\u20138.","journal-title":"Methods"},{"key":"711_CR14","doi-asserted-by":"publisher","first-page":"374","DOI":"10.2144\/03342mt01","volume":"34","author":"AI Saeed","year":"2003","unstructured":"Saeed AI, Sharov V, White J, Li J, Liang W, Bhagabati N, et al. TM4: a free, open-source system for microarray data management and analysis. Biotechniques. 2003;34:374\u20138.","journal-title":"Biotechniques"},{"key":"711_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2024.176544","volume":"971","author":"M Azumi","year":"2024","unstructured":"Azumi M, Kusama K, Yoshie M, Nakano S, Tsuru A, Kato T, et al. Involvement of ferroptosis in eribulin-induced cytotoxicity in ovarian clear cell carcinoma. Eur J Pharmacol. 2024;971: 176544.","journal-title":"Eur J Pharmacol"},{"key":"711_CR16","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/s12967-016-1000-z","volume":"14","author":"R Biaoxue","year":"2016","unstructured":"Biaoxue R, Xiguang C, Hua L, Shuanying Y. Stathmin-dependent molecular targeting therapy for malignant tumor: the latest 5 years\u2019 discoveries and developments. J Transl Med. 2016;14:279.","journal-title":"J Transl Med"},{"key":"711_CR17","volume":"21","author":"T Nabekura","year":"2020","unstructured":"Nabekura T, Kawasaki T, Jimura M, Mizuno K, Uwai Y. Microtubule-targeting anticancer drug eribulin induces drug efflux transporter P-glycoprotein. Biochem Biophys Rep. 2020;21: 100727.","journal-title":"Biochem Biophys Rep"},{"key":"711_CR18","doi-asserted-by":"publisher","first-page":"70011","DOI":"10.18632\/oncotarget.11727","volume":"7","author":"T Oba","year":"2016","unstructured":"Oba T, Izumi H, Ito KI. ABCB1 and ABCC11 confer resistance to eribulin in breast cancer cell lines. Oncotarget. 2016;7:70011\u201327.","journal-title":"Oncotarget"},{"key":"711_CR19","first-page":"8987568","volume":"2018","author":"K Yahiro","year":"2018","unstructured":"Yahiro K, Matsumoto Y, Fukushi JI, Kawaguchi KI, Endo M, Setsu N, et al. Class III beta-tubulin overexpression induces chemoresistance to eribulin in a leiomyosarcoma cell line. Anal Cell Pathol (Amst). 2018;2018:8987568.","journal-title":"Anal Cell Pathol (Amst)"},{"key":"711_CR20","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1007\/s12282-021-01224-1","volume":"28","author":"X Teng","year":"2021","unstructured":"Teng X, Hayashida T, Murata T, Nagayama A, Seki T, Takahashi M, et al. A transposon screen identifies enhancement of NF-kappaB pathway as a mechanism of resistance to eribulin. Breast Cancer. 2021;28:884\u201395.","journal-title":"Breast Cancer"},{"key":"711_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.786","volume":"9","author":"M Yoshie","year":"2021","unstructured":"Yoshie M, Ishida A, Ohashi H, Nakachi N, Azumi M, Tamura K. Stathmin dynamics modulate the activity of eribulin in breast cancer cells. Pharmacol Res Perspect. 2021;9: e00786.","journal-title":"Pharmacol Res Perspect"},{"key":"711_CR22","doi-asserted-by":"publisher","first-page":"6080","DOI":"10.3390\/cancers14246080","volume":"14","author":"HP Vicari","year":"2022","unstructured":"Vicari HP, Lima K, Costa-Lotufo LV, Machado-Neto JA. Cellular and molecular effects of eribulin in preclinical models of hematologic neoplasms. Cancers (Basel). 2022;14:6080.","journal-title":"Cancers (Basel)."},{"key":"711_CR23","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1038\/s41416-021-01293-1","volume":"124","author":"A Gris-Oliver","year":"2021","unstructured":"Gris-Oliver A, Ibrahim YH, Rivas MA, Garcia-Garcia C, Sanchez-Guixe M, Ruiz-Pace F, et al. PI3K activation promotes resistance to eribulin in HER2-negative breast cancer. Br J Cancer. 2021;124:1581\u201391.","journal-title":"Br J Cancer"},{"key":"711_CR24","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.bbamcr.2013.12.005","volume":"1843","author":"P Castri","year":"2014","unstructured":"Castri P, Lee YJ, Ponzio T, Maric D, Spatz M, Bembry J, et al. Poly(ADP-ribose) polymerase-1 and its cleavage products differentially modulate cellular protection through NF-kappaB-dependent signaling. Biochim Biophys Acta. 2014;1843:640\u201351.","journal-title":"Biochim Biophys Acta"},{"key":"711_CR25","first-page":"305","volume":"22","author":"LJ Kuo","year":"2008","unstructured":"Kuo LJ, Yang LX. Gamma-H2AX\u2014a novel biomarker for DNA double-strand breaks. In Vivo. 2008;22:305\u20139.","journal-title":"In Vivo"},{"key":"711_CR26","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1517\/14728222.2011.620951","volume":"15","author":"B Belletti","year":"2011","unstructured":"Belletti B, Baldassarre G. Stathmin: a protein with many tasks. New biomarker and potential target in cancer. Expert Opin Ther Targets. 2011;15:1249\u201366.","journal-title":"Expert Opin Ther Targets."},{"key":"711_CR27","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.jphs.2022.09.006","volume":"150","author":"M Azumi","year":"2022","unstructured":"Azumi M, Yoshie M, Nakachi N, Tsuru A, Kusama K, Tamura K. Stathmin expression alters the antiproliferative effect of eribulin in leiomyosarcoma cells. J Pharmacol Sci. 2022;150:259\u201366.","journal-title":"J Pharmacol Sci"},{"key":"711_CR28","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1248\/bpb.b22-00251","volume":"45","author":"M Azumi","year":"2022","unstructured":"Azumi M, Yoshie M, Takano W, Ishida A, Kusama K, Tamura K. The impact of eribulin on stathmin dynamics and paclitaxel sensitivity in ovarian cancer cells. Biol Pharm Bull. 2022;45:1627\u201335.","journal-title":"Biol Pharm Bull"},{"key":"711_CR29","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1080\/01913123.2024.2371821","volume":"48","author":"G Tanriverdi","year":"2024","unstructured":"Tanriverdi G, Kaleci B, Yavuz F, Sahin H, Purelku M, Yazici Z, et al. The effects of the combination of temozolomide and Eribulin on T98G human glioblastoma cell line: an ultrastructural study. Ultrastruct Pathol. 2024;48:323\u201337.","journal-title":"Ultrastruct Pathol"},{"key":"711_CR30","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987\u201396.","journal-title":"N Engl J Med"},{"key":"711_CR31","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.gendis.2016.04.007","volume":"3","author":"SY Lee","year":"2016","unstructured":"Lee SY. Temozolomide resistance in glioblastoma multiforme. Genes Dis. 2016;3:198\u2013210.","journal-title":"Genes Dis"},{"key":"711_CR32","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/s00280-024-04711-2","volume":"94","author":"Z Eroglu","year":"2024","unstructured":"Eroglu Z, Synold T, Badie B, Liu A, Chowdhury A, Kilpatrick J, et al. An intracerebral microdialysis study to determine the neuropharmacokinetics of eribulin in patients with metastatic or primary brain tumors. Cancer Chemother Pharmacol. 2024;94:807\u201313.","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-025-00711-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43440-025-00711-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-025-00711-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T13:11:06Z","timestamp":1747055466000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43440-025-00711-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,8]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["711"],"URL":"https:\/\/doi.org\/10.1007\/s43440-025-00711-y","relation":{},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"type":"print","value":"1734-1140"},{"type":"electronic","value":"2299-5684"}],"subject":[],"published":{"date-parts":[[2025,3,8]]},"assertion":[{"value":"18 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}